SAGE has run several PPD & MDD trials with 547 and the oral 217 with all showing outstanding reductions in the HAM-D. Marinus has nothing to show. SAGE's oral 217 is a 30mg QD tx while MRNS 's oral Ganaxolone is a 900mg BID dose. SAGE has decided to enlarge the P2 for 217 in PPD so it could qualify as a registration trial. So if Marinus ever gets good numbers for its IV in PPD it won't help because SAGE would then advance its oral 217 towards PPD which immediately kills off both Brexanolone and Ganaxolone because of their higher cost & IV inconvenience. In other words Marinus can't win even if its IV drug works great in PPD.
News 
Market Data 
Discover 
